Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Machine Learning for Predicting Colorectal Cancer and Advanced Colorectal Polyps
Malik, Sheza , Naqvi, Arsalan, Tenorio, Bettina Gabrielle , Farrukh, Faiqa, Naqvi, Arsalan, Tariq, Raseen , Adler, Douglas G.

Journal of Clinical Gastroenterology | May 28, 2025 | Volume: 60 | Issue: 3 | Pages: 237-246

10.1097/mcg.0000000000002172 | PMID 40434809 Get It

Introduction: Machine learning (ML) has become increasingly pivotal in health care, particularly in colorectal cancer (CRC) detection and diagnosis with the use of predictive models and artificial intelligence-assisted colonoscopies. This study evaluates the efficacy of ML models in predicting the risk for CRC and advanced colorectal polyps (ACP) before colonoscopy. Methods: A systematic literature review was conducted following PRISMA guidelines, focusing on studies using ML for CRC and ACP prediction. Data extraction regarding study type, ML methodology, quality of data, and bias assessment was in line with the CHARMS checklist. Meta-analysis was also performed to assess the performance of models for the prediction of CRC, adenoma, or both. Results: This systematic review included 14 studies with 3618 median patients (333 to 263,879). Our study demonstrated considerable heterogeneity in methodologies and outcomes, with area under the receiver operating characteristic (AUROC) ranging from 0.6 to 1. The derivation+validation cohorts showed a pooled sensitivity of 0.832 (95% CI: 0.755-0.889) and specificity of 0.802 (95% CI: 0.722-0.863), with an overall AUROC of 0.883. Conclusion: The review underscores the significant role of ML in CRC and ACP diagnosis and its routine use could efficiently direct high-risk patients to timely colonoscopies and spare the low-risk ones from unnecessary procedures. Despite the promise shown, the variability in methodologies and outcomes highlights the need for standardized approaches and further investigation in this field.
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
Prat, Aleix , Wright, Jean, Recht, Abram, Weiss, Anna , Tjoe, Judy A., Feldman, Sheldon , Smith, Mary Lou , O’Sullivan, Ciara C. , Sardesai, Sagar , Sardesai, Sagar , Prat, Aleix , Tung, Nadine , Zhao, Fengmin , DeMichele, Angela , Winer, Eric P. , Recht, Abram , Rocque, Gabrielle B. , Villagrasa, Patricia , Badve, Sunil , Partridge, Ann H. , Miller, Kathy D. , Carey, Lisa A. , Wolff, Antonio C.

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 501-501

10.1200/jco.2025.43.16_suppl.501 Get It

501 Background: EA1181 (NCT04266249) is a single-arm trial of neoadjuvant THP for patients with clinical anatomic stage II/III HER2+ breast cancer; patients with cT4 or cN3 disease were excluded . Assessing the primary endpoint, 3-year recurrence-free survival in patients with a pCR (ypT0/Tis, ypN0), requires longer follow-up. Here, we present results for the secondary objective of pCR rate and its relation to clinicopathologic factors and the HER2DX pCR likelihood score (Reveal Genomics) derived from gene expression and clinical features. Methods: Patients received 4 cycles of trastuzumab and pertuzumab (HP) with weekly paclitaxel (12 weeks) or docetaxel (q3w x 4), followed by surgery. Clinicopathologic features were assessed for all patients and HER2DX pCR score (stratified by ER status) was determined using the diagnostic biopsy in a representative subset of study participants. Results: 2175 patients were enrolled. Median age was 55 years (range 22-88 years); 58% had clinical stage IIA, 33% stage IIB, and 9% stage III. 45% had nodal involvement (mostly cN1). 781 tumors were HER2+/ER- and 1394 HER2+/ER+ (locally tested ). 2141 patients started THP, for whom the pCR rate was 44% overall, 63.7% in HER2+/ER- and 32.4% in HER2+/ER+ tumors. Disease progressed during THP in 16 patients (0.7%). The pCR rate varied inversely to the proportion of cells staining for ER among patients with HER2+/ER+ breast cancer: 1-10%+, 62.5%; 11-69%, 51.6%; ≥70%, 22.5% (p <0.001). The pCR rate was significantly associated with higher grade, especially in HER2+/ER+ disease. T and N stage did not significantly affect pCR rate. Among 569 patients assessed for the HER2DX pCR score, the pCR rate was significantly greater for patients with a higher vs lower score, regardless of ER status (Table). Further correlations and interactions will be presented. Conclusions: Neoadjuvant THP resulted in pCR in nearly two-thirds of pts with clinical stage II/III HER2+/ER- and in one-third with HER2+/ER+ breast cancer. There was no association with clinical stage. Lower ER expression and higher grade were associated with higher pCR rates. The HER2DX pCR score was a significant predictor of pCR, regardless of ER status. Clinical trial information: NCT04266249 . All Participants HER2+/ER- HER2+/ER+ # patients enrolled pCR rate (95% CI) # patients enrolled pCR rate (95% CI) # patients enrolled pCR rate (95% CI) Evaluable Cohort 2141 44%(42-46%) 774 64%(60-67%) 1367 32%(30-35%) HER2DX Cohort 569 48%(44- 52%) 230 69% (63-75%) 339 34%(29-39%) HER2DX pCR-high score 182 (32%) 68%(60-74%) 147 (64%) 70% (62-77%) 36 (11%) 58%(41-74%) HER2DX pCR-medium score 161 (28%) 67% (59- 74%) 70 (30%) 74%(62- 84%) 89 (26%) 61%(50-71%) HER2DX pCR-low score 226 (40%) 19%(14- 25%) 13 (6%) 31%(9-61%) 214 (63%) 18%(13-24%) P-value HER2DX score <0.001 0.010 <0.001
Regenerate stabilization with a photodynamic bone stabilization system after acute shortening and then lengthening: a case report
Wellings, Elizabeth P. , Blair, James A. , Wellings, Elizabeth P

OTA International | May 28, 2025 | Volume: 8 | Issue: 2 | Pages: No page available

10.1097/oi9.0000000000000408 | PMID 40438272 Get It

Abstract Case: A 42-year-old African-American woman sustained a type IIIA open pilon fracture requiring open reduction internal fixation complicated by wound dehiscence. Acute shortening for primary wound closure was performed followed by relengthening in a circular frame. Owing to the patient's intolerance to the circular frame, pre-existing osseous deformity, large body habitus, and soft tissue compromise, conversion to intramedullary stabilization with standard nailing was deemed exceedingly difficult. We describe the use of a photodynamic bone stabilization system allowing for percutaneous entry and implant flexibility for the purpose of early circular frame removal. Conclusion: This case demonstrates successful protection of immature regenerate using a photodynamic bone stabilization system, offering another tool to minimize time spent in a circular frame.
Eosinophilia and basophilia in essential thrombocythemia and polycythemia vera: Clinical, genetic, and prognostic correlates.
Faldu, Priyansh, Yousuf, Muhammad , Abdelmagid, Maymona, Dingli, Sarah, Begna, Kebede H. , Zepeda‐Mendoza, Cinthya , Reichard, Kaaren K. , He, Rong, Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew, Dingli, Sarah, He, Rong , Tefferi, Ayalew

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18600 Get It

e18600 Background: Recent studies have suggested that basophilia in myeloproliferative neoplasms (MPN), in general, and in primary myelofibrosis (PMF), in particular, might be associated with poor prognosis. In the current study, we examined for clinical and genotype correlates as well as the prognostic impact of absolute eosinophil (AEC) and basophil (ABC) counts in essential thrombocythemia (ET) and polycythemia vera (PV). Methods: Diagnostic criteria were according to the International Consensus Classification. Study patients were selected based on the availability of information on AEC and ABC. Institutional reference range for AEC was 0.03 to 0.48 x 10 9 /L and for ABC 0.01 to 0.08 x 10 9 /L. "Eosinophilia" was defined as an AEC of ≥0.5 x 10 9 /L. "Basophilia" was evaluated both at an ABC of ≥0.1 x 10 9 /L and ABC of ≥0.3 x 10 9 /L, the latter representing 3 x the upper limit of the normal reference range. Results: Essential thrombocythemia 660 patients were considered. Median (range) values for AEC and ABC were 0.2 x 10 9 /L (0-2.8) and 0.07 x 10 9 /L (0-1.7), respectively. On univariate analysis, AEC and ABC, as continuous variables, were predictive of inferior overall (OS; p<0.01 for both) but not leukemia-free (LFS), myelofibrosis-free (MFFS), venous thrombosis-free (VTFS), or arterial thrombosis-free (ATFS) survival. In univariable analysis, AEC ≥0.5 x 10⁹/L and ABC ≥0.1 x 10⁹/L negatively impacted OS (p<0.01 for both); significance was sustained during multivariate analysis that included IPSET risk variables: AEC ≥0.5 x 10⁹/L (p<0.01; HR 1.9) and ABC ≥0.1 x 10 9 /L (p<0.01; HR 1.7). Polycythemia vera 478 patients were considered. Median (range) values for AEC and ABC were 0.27 x 10 9 /L (0-6.5) and 0.12 x 10 9 /L (0-3.2), respectively. In univariable analysis, neither AEC nor ABC, as continuous variables were predictive of OS, LFS, MFFS, VTFS, or ATFS. AEC ≥0.5 x 10⁹/L also did not have any impact on disease progression or thromboses. However, ABC ≥0.1 x 10 9 /L was associated with a lower risk of post-diagnosis arterial thrombosis (p=0.03; HR 0.6), and ABC ≥0.3 x 10 9 /L was predictive of inferior LFS (p<0.01; HR 6.5) and MFFS (p<0.01; HR 2.5). ABC ≥0.3 x 10 9 /L sustained prognostic relevance in LFS (p<0.01; HR 7.6) during multivariable analysis that included leukocytosis, platelet count, basophil percentage, age, and palpable splenomegaly. Similar findings were noted with regards to MFFS for ABC ≥0.3 x 10 9 /L (p=0.01; HR 2.3) when compared against palpable splenomegaly and age. Conclusions: The current study suggests that AEC ≥0.5 x 10 9 /L and ABC ≥0.1 x 10 9 /L in ET are independently associated with shortened overall survival, while basophilia (ABC ≥0.3 x 10 9 /L) in PV is an independent predictor of leukemic and myelofibrotic disease progression.
Call for a Translational Orthobiologics Fellowship in the Era of Regenerative Medicine
Strader, Shannon , Villasenor, Andrew, Wyles, Saranya P. , Chandan, Priya , Terzic, Carmen M., Bean, Allison , Wyles, Saranya, Terzic, Carmen, Strader, Shannon R , Master, Zubin

American Journal of Physical Medicine & Rehabilitation | May 28, 2025 | Volume: 104 | Issue: 9 | Pages: 831-837

10.1097/phm.0000000000002782 | PMID 40434440 Get It

Abstract Regenerative medicine is a rapidly advancing field, particularly within the field of physical medicine and rehabilitation. While orthobiologics are currently being used in clinical practice, there remains a need for high-quality clinical trials and translational research to standardize treatments and improve patient outcomes. Education is vital for streamlining development of evidence-based, practical, and effective treatments. In this article, we highlight the need for a 1-yr advanced fellowship in translational orthobiologics aiming to create a standardized core curriculum targeting physicians involved in treating musculoskeletal diseases. The fellowship’s objectives include advancing translational orthobiologics research, ethical considerations, and promoting effective communication regarding orthobiologic therapies. Such a program would serve as a foundation for physicians interested in conducting clinically oriented orthobiologics research for musculoskeletal disorders while improving the development of safe and effective therapeutics related to musculoskeletal disorders.
Discussion: Spontaneous Recovery of Active Shoulder External Rotation in Patients with Brachial Plexus Birth Injury
Spinner, Robert J. , Pulos, Nicholas , Shin, Alexander Y.

Plastic & Reconstructive Surgery | May 28, 2025 | Volume: 155 | Issue: 6 | Pages: 1054e-1055e

10.1097/prs.0000000000011987 | PMID 40434663 Get It

Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function
Yang, David Yi , Lupianez‐Merly, Camille , Jencks, Kara J. , Busciglio, Irene, Eckert, Deborah J., Ryks, Michael, Dyer, Roy B. , Vizenor, Brady A., Zhao, Yuxi , Sapone, Anna, Rooks, Michelle, Gale, Jeremy D. , Camilleri, Michael , Dilmaghani, Saam , Eckert, Deborah, Dyer, Roy, Camilleri, M , Jencks, Kara , Vizenor, Brady A.

Clinical and Translational Gastroenterology | May 28, 2025 | Volume: 16 | Issue: 7 | Pages: e00865

10.14309/ctg.0000000000000865 | PMID 40434309 Get It

INTRODUCTION: Altered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs. METHODS: We conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of castor oil (CO) (and its ingredient ricinoleic acid) at 750, 1,500, or 3,000 mg daily doses on IP. Permeability was assessed using validated 13 C-mannitol and lactulose urine excretion at 0–2, 8–24, and 0–24 hours after oral administration. RESULTS: Permeability analysis across all groups demonstrated significant difference among the groups for 0–2 hours 13 C-mannitol, 0–24 hours 13 C-mannitol, and borderline significant difference for 2–8 hours 13 C-mannitol ( P = 0.060) and 0–24 hours lactulose ( P = 0.056). Direct comparison of 3,000 mg CO vs placebo ( t test) demonstrated higher excretion of 13 C-mannitol and lactulose at 0–2, and 0–24 hours, and lactulose at 2–8 hours. DISCUSSION: CO may perturb small intestinal and colonic permeability in healthy adults.
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and
Arbour, Kathryn C. , George, Ben , Henry, Jason T. , Leventakos, Konstantinos , Ahnert, Jordi Rodon, Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Wozniak, A., Chin, Curtis D., Mazzei, Antonella , Hu, Zheyi , Simpson, Tyler R., Dickinson, Adam , Jänne, Pasi A. , Ahnert, Jordi Rodon, Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Chin, Curtis

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2025.43.16_suppl.3011 Get It

3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP– wild-type cells. In the first-in-human phase 1/2 CA240-0007 study in advanced, unresectable or metastatic solid tumors with homozygous MTAP -del, BMS-986504 was found to be well tolerated and demonstrated antitumor activity in multiple tumors. Here, we report clinical results and the first PK and PD analyses of BMS-986504 from the dose escalation and expansion phases of CA240-0007. Methods: Pts with measurable/evaluable disease and no available treatment (Tx) with curative intent were enrolled; 7 doses were evaluated (50 to 800 mg) in dose escalation. Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), safety, PK, PD, including plasma SDMA were assessed. Results: As of 2 Dec 24, 152 heavily pretreated pts were enrolled across all doses: NSCLC (n = 34), PDAC (n = 41), cholangiocarcinoma (n = 12), and mesothelioma (n = 12) were the most common tumor types. With a median f/u of 9.0 mo (95% CI 7.6–9.9), continued durable antitumor activity and deepening tumor regression were seen across tumor types and doses (ORR = 23%, DCR = 70%, median DOR = 10.5 mo, TTR = 4.6 mo). No new safety signals were identified. Most Tx-related adverse events (TRAEs) were grade (Gr) 1 or 2; 13% had Gr ≥ 3 TRAEs (Gr 3 = 12%, Gr 4 = < 1%, Gr 5 = 0). Doses from 50 to 600 mg QD were assessed for PK/PD. The AUC (0-24) after multiple doses was approximately dose proportional at 200 to 600 mg, and the terminal t 1/2 after a single dose was approximately 24 h (table). There were dose-dependent reductions in predicted plasma SDMA, with the 400 and 600 mg doses approaching the plateau. Conclusions: With longer f/u, BMS-986504 continued to show increasingly durable antitumor activity. BMS-986504 demonstrated a favorable PK/PD profile, supporting QD dosing at 400 and 600 mg. These results support further investigation of BMS-986504 at 400 and 600 mg QD as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP -del. Clinical trial information: NCT05245500 . PK and PD. 50 mg QD 100 mg QD 200 mg QD 400 mg QD 600 mg QD PK after multiple doses t max a (min–max), h 2.0 (2.0–4.0)n = 3 2.0 (1.0–2.0)n = 3 2.0 (0.5–6.0)n = 8 2.0 (0.5–4.0)n = 10 2.0 (1.0–6.0)n = 10 C max , b ng/mL 107n = 3 377n = 3 685n = 8 1240n = 10 2110n = 10 AUC (0-24) , b h∙ng/mL 948 n = 3 3060 n = 3 7150 n = 7 11,800n = 10 26,700n = 9 AUC (0-24) , b,c h∙ng/mL/mg 19.0n = 3 30.6n = 3 35.8n = 7 29.5n = 10 44.6n = 9 Terminal t 1/2 after single dose, d h 21.7 n = 1 80.7 n = 1 21.5 n = 14 21.7 n = 14 24.1 n = 1 PD Translational exposure targets (C avgss ), X 0.08 0.21 0.5 1.1 1.7 Predicted plasma SDMA reduction, a % (90% PI) 30.0 (23.2–37.8) 38.8 (27.1–47.5) 48.3 (42.0–53.0) 55.0 (50.7–57.6) 57.4 (54.3–59.0) a Median. b Geometric mean. c Dose-normalized. d Arithmetic mean.
Integrated transcriptomic analysis of human induced pluripotent stem cell-derived osteogenic differentiation reveals a regulatory role of KLF16
Ying, Ru , Ma, Meng , Kriti, Divya , Cohen, Ninette, D’Souza, Sunita L. , Schaniel, Christoph , Perrine, Susan M. Motch , Pichurin, Oksana , Pinto, Dalila , Holmes, Greg , Schadt, Eric E. , Bakel, Harm van , Ru, Ying, Zhou, Xianxiao , Kuo, Sharon , Housman, Genevieve , Zhang, Bin , Jabs, Ethylin W , Wu, Meng

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.106265.1 Get It

Abstract Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the transcriptomic changes and identify novel regulatory genes involved in osteogenic differentiation, we differentiated mesenchymal stem cells (MSCs) derived from 20 human iPSC lines into preosteoblasts (preOBs) and osteoblasts (OBs). We then performed transcriptome profiling of MSCs, preOBs and OBs. The iPSC-derived MSCs and OBs showed similar transcriptome profiles to those of primary human MSCs and OBs, respectively. Differential gene expression analysis revealed global changes in the transcriptomes from MSCs to preOBs, and then to OBs, including the differential expression of 840 genes encoding transcription factors (TFs). TF regulatory network analysis uncovered a network comprising 451 TFs, organized into five interactive modules. Multiscale embedded gene co-expression network analysis (MEGENA) identified gene co-expression modules and key network regulators (KNRs). From these analyses, KLF16 emerged as an important TF in osteogenic differentiation. We demonstrate that overexpression of Klf16 in vitro inhibited osteogenic differentiation and mineralization, while Klf16+/- mice exhibited increased bone mineral density, trabecular number, and cortical bone area. Our study underscores the complexity of osteogenic differentiation and identifies novel regulatory genes such as KLF16, which plays an inhibitory role in osteogenic differentiation both in vitro and in vivo.
Integrated transcriptomic analysis of human induced pluripotent stem cell-derived osteogenic differentiation reveals a regulatory role of KLF16
Ying, Ru , Ma, Meng , Cohen, Ninette, D’Souza, Sunita L. , Schaniel, Christoph , Perrine, Susan M. Motch , Pichurin, Oksana , Holmes, Greg , Schadt, Eric E. , Zhang, Bin , Ru, Ying, Zhou, Xianxiao , Kriti, Divya , Kuo, Sharon , Pinto, Dalila , Housman, Genevieve , Bakel, Harm van , Jabs, Ethylin W , Wu, Meng

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.106265 Get It

Abstract Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the transcriptomic changes and identify novel regulatory genes involved in osteogenic differentiation, we differentiated mesenchymal stem cells (MSCs) derived from 20 human iPSC lines into preosteoblasts (preOBs) and osteoblasts (OBs). We then performed transcriptome profiling of MSCs, preOBs and OBs. The iPSC-derived MSCs and OBs showed similar transcriptome profiles to those of primary human MSCs and OBs, respectively. Differential gene expression analysis revealed global changes in the transcriptomes from MSCs to preOBs, and then to OBs, including the differential expression of 840 genes encoding transcription factors (TFs). TF regulatory network analysis uncovered a network comprising 451 TFs, organized into five interactive modules. Multiscale embedded gene co-expression network analysis (MEGENA) identified gene co-expression modules and key network regulators (KNRs). From these analyses, KLF16 emerged as an important TF in osteogenic differentiation. We demonstrate that overexpression of Klf16 in vitro inhibited osteogenic differentiation and mineralization, while Klf16+/- mice exhibited increased bone mineral density, trabecular number, and cortical bone area. Our study underscores the complexity of osteogenic differentiation and identifies novel regulatory genes such as KLF16, which plays an inhibitory role in osteogenic differentiation both in vitro and in vivo.